Invex Therapeutics (ASX:IXC) Net Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Invex Therapeutics's Net Income for the six months ended in Dec. 2024 was A$-0.36 Mil. Invex Therapeutics's Revenue for the six months ended in Dec. 2024 was A$0.00 Mil. Therefore, Invex Therapeutics's net margin for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Invex Therapeutics's Net Margin % or its related term are showing as below:

ASX:IXC's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -119.77
* Ranked among companies with meaningful Net Margin % only.

Invex Therapeutics Net Margin % Historical Data

The historical data trend for Invex Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Net Margin % Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Net Margin %

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Net Margin %	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of Invex Therapeutics's Net Margin %

For the Biotechnology subindustry, Invex Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's Net Margin % falls into.

Save Embed

;

Save Embed

;

Invex Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Invex Therapeutics's Net Margin for the fiscal year that ended in Jun. 2023 is calculated as

Net Margin	=	Net Income (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-7.75	/	0
	=	%

Invex Therapeutics's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-0.357	/	0
	=	%

Invex Therapeutics (ASX:IXC) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Invex Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.